drugset / Trial / NCT01110421

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421

Phase 3 Terminated 7 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.

Timeline

Start
2010-12
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefepime Small molecule 50 mg/kg Intravenous
Subject Doripenem Small molecule 20 mg/kg Intravenous
Background Amoxicillin/clavulanate potassium Unknown Oral